Search results
Showing 1651 to 1665 of 2548 results for methods
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]
Discontinued Reference number: GID-TA10869
Discontinued Reference number: GID-TAG370
This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.
View quality statements for QS41Show all sections
Sections for QS41
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Specialist referral
- Quality statement 3: DNA testing
- Quality statement 4: Diagnosis in children under 10 years
- Quality statement 5: Cascade testing
- Quality statement 6: Drug treatment in adults
- Quality statement 7: Drug treatment in children
Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]
Discontinued Reference number: GID-TAG399
Tegaderm CHG securement dressing for vascular access sites (MIB231)
NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)
NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
Discontinued Reference number: GID-TA10267
Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]
Discontinued Reference number: GID-TA11205
Discontinued Reference number: GID-TAG250
In development Reference number: GID-TA11443 Expected publication date: TBC
In development Reference number: GID-TA11455 Expected publication date: TBC
In development Reference number: GID-TA10780 Expected publication date: TBC